Cancer Aware · Patient & Family Guide

Prognosis, Survival and Living Beyond Cancer

Prognosis describes the likely course of a disease in a group of people with similar features. It cannot tell one person exactly what will happen.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 24 of 25

What you will learn

  • Understand the factors that influence outlook.
  • Distinguish cure, response, overall survival and relative survival.
  • Plan for life after treatment without ignoring uncertainty.

Factors that shape prognosis

Many people with early-stage endometrial cancer are treated successfully with curative intent. Outlook depends on stage, histology, grade, LVSI, molecular group, completeness of treatment and general health. A pathogenic POLE mutation often indicates a favourable early-stage group, while p53-abnormal invasive disease can carry greater recurrence risk. NSMP is diverse, and grade and ER expression refine its assessment.

The effect of a molecular finding depends on context. Advanced POLE-mutated cancer is not automatically equivalent to low-risk uterus-confined disease. MMRd may predict sensitivity to immunotherapy in appropriate settings without guaranteeing cure. A tumour's biology helps guide choices but does not remove uncertainty.

Understanding survival language

TermWhat it measures
Overall survivalTime until death from any cause, usually from diagnosis or trial entry
Progression-free survivalTime without progression or death in a study
Recurrence-free survivalTime without recurrence after treatment, with exact definitions varying by study
Relative survivalSurvival compared with a similar general population
Response rateProportion with tumour shrinkage meeting study criteria
CureCancer does not return over the long term; not established by a single scan

A complete response means no detectable cancer by the assessment used; microscopic disease may still be possible. “No evidence of disease” is encouraging but is not a promise. Conversely, a person living with controlled metastatic disease can have meaningful time and good quality of life even when treatment is not expected to cure.

Why this chapter avoids a single survival percentage

Public statistics may combine different uterine histologies, older staging systems and treatment eras. A localized/regional/distant registry category is not identical to FIGO 2023. New immunotherapy treatments may not be fully reflected in older survival data. Giving one percentage without these details could mislead rather than inform.

If your clinician uses a statistic, ask which population and years it represents, whether it is overall or relative survival, and how similar those patients are to you. Trial hazard ratios are not personal probabilities. Cross-trial comparisons can be misleading because eligibility, prior treatment and follow-up differ.

Fertility, menopause and sexual wellbeing

Loss of fertility can cause grief even when treatment is successful. Early menopause may affect sleep, sexual comfort, mood, cardiovascular and bone health. Ask for individualized advice about symptom management and reproductive options before treatment when possible. After treatment, rehabilitation and counselling can help with vaginal discomfort, body image and changes in intimacy.

There is no deadline for emotional recovery. Family members may expect life to return to normal before fatigue or fear has settled. Explaining specific needs—rest, help with appointments, privacy or practical assistance—can be more useful than a general instruction to “stay positive.” Persistent low mood or anxiety deserves professional support.

Returning to everyday life

A gradual return to work, exercise and caregiving may be easier than an abrupt full schedule. Discuss adjustments for neuropathy, bowel symptoms, lymphoedema or fatigue. Financial and employment advice can be part of survivorship care. Choose sustainable habits rather than restrictive diets or expensive products promising to prevent recurrence.

Questions and take-home messages

Ask what is known about your risk, what remains uncertain and which actions are useful now. It is reasonable to want detailed numbers or to prefer a broader explanation. The team should respect that preference and revisit the discussion as results, treatment response and your priorities evolve.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy